Analysts expect Marker Therapeutics to report Q3 2026 revenue of $2.12 million and a loss of $0.12 per share, as the stock trades around $0.93 compared to a consensus price target of $10.00.
Investors are primarily focused on clinical updates for the MT-601 multi-antigen T cell therapy, particularly following a recent $2.6 million FDA grant to support its Phase 1 pancreatic cancer study. The company has recently highlighted expanded manufacturing capabilities through its partnership with Kincellis and maintains a history of frequently beating analyst earnings estimates.
Management's commentary on the current cash runway and developmental milestones for its oncology pipeline will be critical for supporting its "Strong Buy" analyst rating.